In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. More contributors will likely be enrolled within the identified monotherapy dosign regimen. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "increase-on" therapy. In https://horacev000isd2.lotrlegendswiki.com/user